Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Logovinsky

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Physical Review Letters|December 23, 1985
Structure and bonding in small silicon clustersRaghavachari, Logovinsky
Journal of Fluorescence|November 19, 2013
Fluorescence line narrowed spectra of Zn and metal-free cytochrome cV Logovinsky, A D Kaposi, J M Vanderkooi
Biochimica Et Biophysica Acta|February 13, 1993
Native and denatured Zn cytochrome c studied by fluorescence line narrowing spectroscopyV Logovinsky, A D Kaposi, J M Vanderkooi
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's diseaseAndrew Satlin, Jinping Wang, Veronika Logovinsky, et al.
Alzheimer'S Research & Therapy|July 18, 2014
Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's diseaseLars Lannfelt, Christer Möller, Hans Basun, et al.
Alzheimer'S Research & Therapy|April 7, 2016
Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibodyVeronika Logovinsky, Andrew Satlin, Robert Lai, et al.
Journal of Clinical Pharmacology|December 18, 2013
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ-secretase modulator, E2212, in healthy human subjectsYanke Yu, Veronika Logovinsky, Edgar Schuck, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 25, 2016
ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trialsJinping Wang, Veronika Logovinsky, Suzanne B Hendrix, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 16, 2013
Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's diseaseMaria C Carrillo, H Robert Brashear, Veronika Logovinsky, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 29, 2023
The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partners Scientific Board (PPSB)Bruce Albala, Eline Appelmans, Ramona Burress, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Physical Review Letters|December 23, 1985
Structure and bonding in small silicon clustersRaghavachari, Logovinsky
Journal of Fluorescence|November 19, 2013
Fluorescence line narrowed spectra of Zn and metal-free cytochrome cV Logovinsky, A D Kaposi, J M Vanderkooi
Biochimica Et Biophysica Acta|February 13, 1993
Native and denatured Zn cytochrome c studied by fluorescence line narrowing spectroscopyV Logovinsky, A D Kaposi, J M Vanderkooi
Alzheimer'S & Dementia (New York, N. Y.)|October 26, 2017
Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's diseaseAndrew Satlin, Jinping Wang, Veronika Logovinsky, et al.
Alzheimer'S Research & Therapy|July 18, 2014
Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's diseaseLars Lannfelt, Christer Möller, Hans Basun, et al.
Alzheimer'S Research & Therapy|April 7, 2016
Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibodyVeronika Logovinsky, Andrew Satlin, Robert Lai, et al.
Journal of Clinical Pharmacology|December 18, 2013
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ-secretase modulator, E2212, in healthy human subjectsYanke Yu, Veronika Logovinsky, Edgar Schuck, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 25, 2016
ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trialsJinping Wang, Veronika Logovinsky, Suzanne B Hendrix, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 16, 2013
Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's diseaseMaria C Carrillo, H Robert Brashear, Veronika Logovinsky, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 29, 2023
The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partners Scientific Board (PPSB)Bruce Albala, Eline Appelmans, Ramona Burress, et al.
Pageof 2